Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.

ABSTRACT:

Background

Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch^® system in patients with metastatic colorectal cancer (mCRC).

Methods

Treatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D₀, D₁₄, D₂₈, D₄₂, and D₅₆ (EPISPOT assay) and at D₀ and D₂₈ (CellSearch^® system). Progression-free survival (PFS)

SUBMITTER: Mazard T 

PROVIDER: S-EPMC8231886 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature